Allogeneic Transplantation
Multiple Myeloma Trials
COMIRB: 24-2397
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation MajesTEC-4 Protocol
Principal Investigator: Jorge Monge
Eligibility: Ages ≥ 18 plus other inclusion and exclusion criteria.
COMIRB: 24-2523
A Phase 1b/2, Open-label Study of GC012F (AZD0120), a CD19/BCMA Dual CART-cell Therapy, in Adult Subjects with Relapsed/refractory Multiple Myeloma Remission
PI: Jorge Monge
Eligibility: Ages ≥ 18; Received at least three prior MM treatment lines of therapy; Have received as part of their previous therapy a PI and ImiD and an antiCD38 antibody
COMIRB: 26-0510
A Phase 2, open-label, randomized, dose optimization study evaluating the efficacy and safety of belantamab mafodotin administered in combination with cyclophosphamide, bortezomib, and dexamethasone in adult participants with newly diagnosed amyloid light chain amyloidosis (ALANIS)
PI: Jorge Monge
Eligibility criteria are described in the link below.
COMIRB: 26-0679
A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma after 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide)
PI: Dan Sherbenou
Eligibility criteria are described in the link below.
Request an Appointment
If you would like to schedule an appointment, please give us a call.
Our intake coordinator will help you navigate the process of becoming a new patient including helping you obtain the necessary referrals, get the necessary medical records transferred, and coordinate care with your existing physicians. We are available to answer your questions about our clinic, your treatment, and participation in ongoing clinical trials.